Psoriasis is a prevalent, chronic inflammatory skin disease that arises from rapid and excessive growth of keratinocytes induced by abnormal inflammatory responses.
| INTRODUCTION
Psoriasis is a long-standing autoimmune disease manifesting in the skin and (or) joints. 1 Characterized by patches of abnormal skin with silver scale, psoriasis is commonly thought to be an immune-mediated genetic disease that is induced by environmental elements. 2 Psoriasis is related to an uprising danger of psoriatic arthritis, Crohn's disease, cardiovascular disorders, lymphomas, and metabolic syndrome or components of the syndrome. 3 Because of its high prevalence and severe associated comorbidity, psoriasis has been considered as a major global health problem. 4 To date, no effective drug for treating psoriasis is available, and the immunopathogenesis of psoriasis remains to be further explored. 5 The main pathogenesis of psoriasis that leads to hyperproliferation of keratinocytes is because of an interaction of innate and adaptive components of the immune system with resident cutaneous cell types. 6 Being a transcription factor, nuclear factor kappa B (NF-κB) plays a critical role in regulating immune response and other complicated biological processes. 7 It has been speculated to connect the hyperproliferative keratinocytes with the behaviour of immune cells that characterize the psoriatic milieu. 8 In addition, lesion samples, and to a minor degree, psoriatic skin, exhibited elevated levels of activated NF-κB signal pathway when compared with nonpsoriatic skin. 9 Therefore, NF-κB may involve in the pathogenesis of psoriasis, and compounds that specifically target NF-κB may represent a new therapeutic option for psoriasis.
Metformin, the first-line medication in treating of type 2 diabetes, 10 is particularly suitable for overweight patients. 11 Previous studies have demonstrated that metformin inhibited the inflammatory responses via NF-κB signalling pathway in the human vascular endothelial cell. 12 Moreover, recent researches revealed that, by targeting NF-ĸB signal pathway, metformin exerted antiproliferative and antimetastatic effects against cholangiocarcinoma. 13 These may lead us to conjecture that metformin might possess a potential role on alleviating the inflammatory response in psoriasis. The objective of our research was to demonstrate the anti-inflammatory effects of metformin in HaCaT cells via NF-κB signalling pathway, which might provide a promising therapeutic approach for the treatment of psoriasis.
| MATERIALS AND METHODS

| Antibodies and reagents
The below antibodies were employed: Anti-IL-6 (sc-65989), anti-IL-1β
(sc-12742), anti-IκBα (sc-1643), anti-IKKα (sc-7606), and anti-actin (sc-47778) were purchased from Santa Cruz Biotechnology. Anti-p65
(8242), phospho-NF-κB p65 (Ser536) (3033), anti-H3 (4499), and anti-β-tubulin (5666) were bought via Cell Signalling. Anti-TNFα (ab9739) and anti-IL-8 (ab154390) were purchased from Abcam.
Tumour necrosis factor-α (TNFα) (ALX-522-008-C050) was purchased from Enzo Life Sciences, and BI605906 (HY-13019) was purchased from MedChemExpress.
| Cell culture
HaCaT cells were cultured in Dulbecco's modified Eagle media (DMEM), which was added with 10% fetal bovine serum (Biological Industries) and penicillin-streptomycin (100 UI/mL-100 μg/mL). Cells were maintained at 37°C in an atmosphere of 95% air/5% CO2.
| Reverse transcription-quantitative polymerase chain reaction
HaCaT cells were first starved without serum overnight, then were treated with or without 2mM metformin or 10μM BI605906 for 
| Western blot
The protein expression levels of TNFα (1:1000), IL-6 (1:1000), IL-8
(1:1000), and IL-1β (1:1000) were detected in HaCaT cells by western blot analysis. HaCaT cells were first starved without serum overnight, then treated with 0.5, 2, and 5mM metformin for 3 hours. TNFα (10 ng/ml) was added at the last 15 minutes of metformin treatment.
The expression levels of p65 (1:500), H3 (1:2000) , and anti-β-tubulin 
| Immunostaining
Presenting to 2mM metformin or not, HaCaT cells were cultured in it for 3 hours before analysis. TNFα (10 ng/ml) was added at the last 15 minutes of metformin treatment. Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), and then were permeabilized by methanol treatment for 15 minutes, which was also blocked with 10% goat serum in PBS. Before applying Alexa-fluor 594
anti-mouse IgG1 antibody, which was bought from Molecular Probes, Eugene, Oregon, cells were incubated with primary antibody anti-p65
(1:50). DAPI was used for nuclear staining. In order to visualize immunostained cells, a Nikon IX 710 fluorescence microscope was used.
| Luciferase assay
Transfected with 100 ng pGMNF-Κb-Luc plasmids and 10 ng of an internal control plasmid pRL-TK, HaCaT cells were incubated with or without 2mM metformin or 10 μM BI605906 for 12 hours before harvest. TNFα (10 ng/ml) was added for 6 hours before harvest.
After transfection, luciferase assays were performed for 36 hours.
Luciferase activity was assayed by a dual-specific luciferase assay kit from Promega.
| Statistical analysis
All data was shown by mean ± SEM. Between samples, differences were explored by the two-tailed Student's t-test. Statistical significance was accepted at P < 0.05.
3 | RESULTS
| Metformin inhibits TNFα-induced inflammatory responses in HaCaT cells
To address whether metformin has an effect on psoriasis, we determined to examine the production of pro-inflammatory cytokines in
HaCaT cells, a cell line used for the study of pathological changes in the prepsoriatic skin. 14 We treated the cells with metformin and measured the levels of critical cytokines at both the mRNA and proteins levels. The results showed that the mRNA levels of TNFα, IL-6, IL-8, and IL-1β were decreased with the treatment of different dosages of metformin in response to TNFα stimulation ( Figure 1A) . Consistently, the protein levels of IL-6, IL-8, and IL-1β were remarkably decreased by the treatment of metformin in HaCaT cells induced with TNFα ( Figure 1B and 1C) . Interestingly, we observed the treatment with higher dosage of metformin maintained the mRNA and protein of these cytokines at a basal level. Taken together, these results suggest that treatment with metformin exhibits an inhibitory effect on TNFα-induced inflammatory response.
| Metformin inhibits the nuclear localization of p65
TNFα induced the production of cytokines by activation of NF-κB. 15 To explore whether metformin inhibited TNFα-induced inflammatory responses via targeting NF-κB signalling pathway, we examined the activation of NF-κB. For this purpose, we analysed the nuclear translocation of p65, a subunit of the nuclear factor NF-κB. An immunostaining revealed that p65 was localized in the nucleus after the treatment with TNFα. However, p65 remained in the cytoplasm after the addition of metformin in the presence of TNFα treatment ( Figure 2A ). These results suggested that metformin remarkably suppressed the nuclear translocation of p65 induced by TNFα. To further illustrate the role of metformin in p65 translocation, we examined the p65 protein levels in the nuclear and cytoplasmic extracts from
HaCaT cells by a western blot analysis. The result showed that p65 was mainly presented in the cytoplasm before the TNFα treatment, similar to the distribution of β-tubulin, a specific cytoplasmic protein ( Figure 2B , lane 1), but was clearly detected in the nuclear components, which is coupled by the localization of H3, a specific protein in the nucleus, after the treatment of TNFα ( Figure 2B, lane 6) . However, the translocated p65 protein was dramatically blocked after the addition of metformin in the presence of TNFα ( Figure 2B , comparing lanes 8 to 6, Figure 2C ). Taken together, we concluded that metformin suppressed the NF-κB-mediated inflammatory responses by inhibiting the nuclear localization of p65.
| Metformin suppresses NF-κB signalling by inhibiting the degradation of IκBα
To verify the inhibitory effect of metformin on NF-κB signalling path, luciferase activity assay with pGMNF-Κb-Luc plasmid was performed.
The relative luciferase activity was remarkably lowered when the
HaCaT cells were applied with metformin, and the inhibitory effect was dose-dependent ( Figure 3A) . The findings of the analysis suggested that metformin inhibited the transcription activity of NF-κB.
To identify the molecular mechanism of the inhibitory effects of metformin on NF-κB signalling, we examined the protein levels of 
| Effects of metformin on NF-κB signalling are comparable with the specific IKKβ inhibitor BI605906
BI605906, a novel inhibitor of IKKβ, inhibits the TNFα-dependent IκB degradation and expression of pro-inflammatory mediators. We HaCaT cells were first starved without serum overnight, then treated with 0.5, 2, and 5mM metformin for 3 hours. TNFα (10 ng/ml) was added at the last 15 minutes of metformin treatment. Each value represents the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus the control group. Met, Metformin FIGURE 2 Metformin inhibits the nuclear translocation of p65. Cellular localization of p65 was analysed by A, immunofluorescence and B, C, western blot. HaCaT cells were cultured in the absence or presence of 2mM metformin for 3 hours before analysis. TNFα (10 ng/ml) was added at the last 15 minutes of metformin treatment. DAPI showed nucleus. β-tubulin and H3 were loading controls for cytoplasm and nuclear fractions. Cy, cytoplasm; Nu, nucleus. scale bars, 50 μm showed that the expression of TNFα, IL-6, IL-8, and IL-1β was increased upon the stimulation with TNFα, whereas it was strongly inhibited by both metformin and BI605906 treatment ( Figure 4A ). In addition, both the metformin and BI605906 treatment suppressed the transcription activity of NF-κB ( Figure 4B ). Altogether, we proved that metformin inhibited the TNFα-dependent NF-κB inflammatory signalling, which was comparable with the specific IKKβ inhibitor BI605906. These data indicate that metformin may serve as a novel therapeutic target for treating the NF-κB-mediated inflammatory responses.
| DISCUSSION
As a chronic inflammatory disease, psoriasis primarily affects the skin and has a systemic pathological effect. 16 Psoriasis patients may have severe complications and physical discomfort, leading to adverse effects on quality of life. 17 Emerging evidence suggests that psoriasis is associated with depression, arthritis, inflammatory bowel disease, and cardiovascular disease. 18 In addition, the costs related to psoriasis have created a considerable economic burden, indicating an important and urgent need for more economical and effective treatment. 19 Abnormally excessive and rapid growth of the keratinocytes accounts for the skin lesion of psoriasis. 20 Commonly, skin cells are replaced every 28 to 30 days; however, in patients with psoriasis, skin cells are replaced every 3 to 5 days. 21 These alterations are believed to originate from the prematurity of keratinocytes stimulated by an inflammatory cascade comprising T cells, macrophages, and dendritic cells. 22 These immune cells secrete inflammatory cytokines involving TNFα, IL-1β, IL-6, IL-22, which stimulate keratinocytes to proliferate. 23 Therefore, understanding the function of inflammatory responses and immune cells in psoriasis may be an important hint to cure this intricate disease.
Currently, there is no complete cure for psoriasis, and numerous treatments could only help manage the disease. Both relieving the systemic inflammatory burden of psoriasis and restoring the skin intact are the ultimate aim of systemic therapy. 24 Previous studies have
shown that methotrexate, cyclosporine, and oral retinoids, such as acitretin, are the conventional systemic treatment options for psoriasis. 24 However, the widespread application of these drugs is limited by inadequate clinical efficacy, safety concerns, or both. 25 The high dose and/or long-term use of the traditional therapies for psoriasis with drug toxicities, which can lead to end-organ damage, lead to the inability to meet desired treatment goals. 26 With continuous exploration of the involvement of cytokines in the aetiology of psoriasis, new biologic agents that precisely target TNFα and IL-12/23
have been developed. 27 Although biologic agents have the ability to improve the therapeutic effect, they are, however, not effective to all individuals with psoriasis. 28 Therefore, the detailed mechanisms involved in the genesis of psoriatic lesions remain to be elucidated, and new therapeutic targets need to be developed.
FIGURE 4
Effects of metformin on nuclear factor kappa B (NF-κB) signalling is comparable with the specific IKKβ inhibitor BI605906. A, The mRNA levels of tumour necrosis factor-α (TNFα), IL-6, IL-8, and IL-1β were tested by quantitative polymerase chain reaction (qPCR). HaCaT cells were first starved without serum overnight, then were treated with or without 2mM metformin or 10 μM BI605906 for 3 hours. TNFα (10 ng/ml) was added at the last 15 minutes of metformin or BI605906 treatment. B, HaCaT cells were transfected with the pGMNF-Κb-Luc plasmids. Cells were incubated with or without 2mM metformin or 10 μM BI605906 for 12 hours before harvest. TNFα (10 ng/ml) was added 6 hours before harvest. Luciferase assays were performed 36 hours after transfection. Each value represents the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus the control group. Met, Metformin; BI, BI605906
Metformin, the most widely prescribed oral antidiabetic agent, has been used for nearly a century. 29 Recently, emerging studies on preclinical and clinical trials have shown that metformin exhibits therapy effects on chronic inflammation through improving metabolic parameters such as hyperglycemia, insulin resistance, and atherogenic dyslipidemia. Moreover, metformin also keeps anti-inflammatory effects. 30 A study demonstrated that metformin could retard inflammatory response by inhibiting the NF-κB signal pathway through targeting AMP-activated protein kinase (AMPK)-dependent and independent pathways. 30 Additionally, the inhibition of mTOR induced by AMPK and the decreased mitochondrial ROS production on the cellular functions of various immune cell types are the two main therapeutic reasons for metformin to suppress immune responses. 31 In 2008, a research involving 36 702 patients with a first-time psoriasis diagnosis has demonstrated that long-term use of metformin is highly related to reduced psoriasis risk. 32 Our study clearly revealed that metformin remarkably reduce inflammatory cytokines production, including
TNFα, IL-6, IL-8, and IL-1β. Taken together, these findings indicated that metformin was an interesting add-on drug in the treatment of immune-mediated inflammatory diseases, such as psoriasis with immunomodulatory properties and high tolerability.
Experimental evidence has identified the significance of the cyto- Recently, agents that particularly target NF-κB signalling path might be developed and utilized as new therapeutics and drugs for chronic inflammatory diseases such as psoriasis. 36 Normally, inactivated NF-κB normally binds to the inhibitory protein IκBα and is located in the cytoplasm. 37 The enzyme IκB kinase (IKK) could be activated by various extracellular stimulus and subsequently phosphorylate the IκBα, leading to the separation of NF-κB from IκBα and the production of inflammatory cytokines including TNFα, IL-6, and IL-1β. 38 The findings of this study suggested that metformin remarkably suppressed the degradation of IκBα, indicating a potential role of metformin in regulating the proteasome-dependent protein degradation. In conclusion, we demonstrated that metformin significantly decreased the production of inflammatory cytokines and inhibited the nuclear localization of p65. In addition, metformin suppressed the transcriptional activity of NF-κB by suppressing the degradation of IκBα. Furthermore, the metformin's inhibitory effect on NF-κB is comparable with the specific IKKβ inhibitor BI605906. Taken together, our data create fair expectations on metformin as a new effective therapeutic agent in treating psoriasis.
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